Invokana® (canagliflozin) Significantly Reduces the Risk of Renal Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in the Landmark Phase 3 CREDENCE Study

Apr 16 2019

EUROPEAN MEDICAL AND PHARMACEUTICAL TRADE MEDIA ONLY| PDF iconDownload PDF